INOVIO PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
INOVIO PHARMACEUTICALS, INC. (INO) had Debt Securities, Available-for-sale, Amortized Cost of $5.32 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $5.32M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $12.03M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $14.95M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $14.96M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $5.32M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $12.03M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $14.95M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $14.96M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $24.14M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $30.15M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $30.17M 10-K · filed 2026-03-12 |
| 2024-09-30 | $65.19M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $79.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $89.45M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $134.87M 10-K · filed 2025-03-18 |
| 2023-09-30 | $154.58M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $147.84M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $201.96M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $216.45M 10-K · filed 2024-03-06 |
| 2022-09-30 | $272.65M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $317.72M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $307.94M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $331.71M 10-K · filed 2023-03-01 |
| 2021-09-30 | $326.47M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $383.78M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $434.13M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $159.24M 10-K · filed 2022-03-01 |
| 2020-09-30 | $157.91M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $157.27M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $117.79M 10-Q · filed 2020-05-11 |
| 2019-03-31 | $106.71M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $58.07M 10-K · filed 2020-03-12 |
| 2018-09-30 | $66.38M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $81.11M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $75.72M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |